This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Glutaric aciduria type I — GA1 / GCDH deficiency / Glutaryl-CoA dehydrogenase deficiency글루타르산뇨

Contents and key points
ItemDetails
A. Classification codesICD-10: E72.3 | Special Copayment Reduction: V117
B. SynonymsGlutaric acidemia type I (GA1), Glutaryl-CoA dehydrogenase deficiency (GCDH deficiency), Glutaric aciduria type I, GA-I
C. Adult onsetLikelihood of first diagnosis in adulthood: low (caution in low excretors) — mostly diagnosed in childhood with an acute striatal crisis triggered by fever or the like. However, in the pre-screening era and in the low excretor phenotype, diagnosis may be delayed until adulthood. Rare cases first presenting with neurological symptoms (dyskinesia) in adulthood have been reported.
1. History1975: Goodman et al. first described glutaric aciduria → GCDH gene cloned (1994) → tandem MS/MS screening (glutarylcarnitine C5DC) → international guidelines (Kölker 2011, 2017) → mechanism of abnormal subdural space development elucidated.
2. CausesPathogenic variants in the GCDH gene (19p13.2) → glutaryl-CoA dehydrogenase deficiency → blocked degradation pathways of lysine, tryptophan and hydroxylysine → accumulation of glutaric acid and 3-hydroxyglutaric acid. Autosomal recessive.
3. GeneticsGCDH gene (19p13.2): 11 exons. More than 200 variants. p.R402W and p.V400M are common in specific populations (Europe, Native Americans). Low excretor vs high excretor phenotypes. Autosomal recessive.
4. General epidemiologyAbout 1 in 100,000. Higher frequency in specific populations (Oji-Cree First Nations, Amish, southern Germany). Included in tandem MS/MS screening panels (elevated C5DC).
5. PathophysiologyGCDH deficiency → accumulation of glutaric acid and 3-hydroxyglutaric acid → abnormal development of the subdural space → the immature striatum is particularly vulnerable to these toxins → acute damage to the striatum (caudate nucleus, putamen) during catabolic crises such as fever and infection → dyskinesia. Toxicity at GABA receptors and glutamate receptors is also involved.
6. SymptomsAcute striatal crisis triggered by fever or the like between 6 months and 5 years of age: sudden dyskinesia (chorea, dystonia), motor regression. Chronic symptoms: dystonia, developmental delay. Before striatal crisis: may be asymptomatic or have only macrocephaly.
7. SignsBrain MRI: enlarged subdural space (bilateral frontotemporal), damage to the caudate nucleus and putamen (T2 hyperintensity, atrophy). Elevated urinary glutaric acid and 3-hydroxyglutaric acid. Elevated blood/urine C5DC (glutarylcarnitine). Dyskinesia (chorea, athetosis, dystonia).
8. ScreeningNewborn tandem MS/MS: elevated C5DC (glutarylcarnitine). Limited because C5DC may be within the normal range in low excretors. Confirmation: urine organic acids (glutaric acid, 3-hydroxyglutaric acid), GCDH gene testing.
9. DiagnosisUrine organic acid analysis (elevated glutaric acid and 3-hydroxyglutaric acid), plasma acylcarnitines (elevated C5DC), GCDH enzyme activity (leukocytes, fibroblasts), GCDH gene NGS. Brain MRI (enlarged subdural space, striatal damage).
10. TreatmentLow-lysine (low-protein) diet. Carnitine supplementation (L-carnitine). Riboflavin (increases enzyme activity in some patients). Emergency treatment of acute striatal crisis: immediate emergency treatment (emergency regimen) — intensified lysine restriction, high-carbohydrate/glucose supply, hospitalization, symptomatic treatment of dyskinesia. Management of dyskinesia: baclofen, trihexyphenidyl, etc.
11. PrognosisPreventing striatal crisis is the key — if crisis is prevented, normal development without neurological damage is possible. After a striatal crisis, dyskinesia may remain permanently. Early treatment after newborn screening + adherence to the emergency treatment protocol can greatly reduce the incidence of striatal crisis.
12. PreventionEarly diagnosis by newborn screening. Early start of low-lysine diet + carnitine supplementation. Immediate application of the emergency treatment protocol (emergency regimen) during fever or infection. Education on hospitalization criteria for all febrile illnesses. Genetic counseling and family screening.
13. ReferencesKölker S et al. J Inherit Metab Dis. 2011 and 9 other references

1. History

Glutaric aciduria type I (GA1) was recognized as a clinical disease in 1975, when Stephen Goodman, Mario Marini and colleagues first described excessive urinary excretion of glutaric acid in patients with intellectual disability and movement disorders. It was shown that in these patients, glutaryl-CoA dehydrogenase (GCDH) deficiency blocks the degradation pathways of lysine, tryptophan and hydroxylysine, and glutaric acid and 3-hydroxyglutaric acid accumulate in the body.

After the initial description, it was gradually recognized that GA1 causes neurological complications characterized by progressive dystonia and chorea. In particular, in the 1980s–90s, the phenomenon of rapid motor regression after febrile infections or vaccination drew attention, and the concept of naming this an 'acute striatal crisis' was established. With the introduction of brain MRI, selective damage to the caudate nucleus and putamen together with abnormal enlargement of the subdural space were described as imaging features of GA1.

The GCDH gene was cloned in 1994 and confirmed to be located on chromosome 19 (19p13.2). Since then, more than 200 pathogenic variants have been reported, and a founder effect, in which specific variants are frequent in particular ethnic groups, has been observed. The frequency of specific variants is high in southern Germany, the Oji-Cree First Nations of Canada and the Amish population of Pennsylvania. With the introduction of tandem mass spectrometry (MS/MS) newborn screening in the 2000s, elevated blood glutarylcarnitine (C5DC) was established as a screening marker, enabling early diagnosis. International consensus guidelines (lead author Stefan Kölker) were published in 2011 and 2017, establishing the standard of GA1 management. These guidelines emphasized that the combination of a low-lysine diet and carnitine supplementation, together with strict adherence to the emergency treatment protocol during fever, is key to preventing striatal crisis.


2. Causes

Glutaric aciduria type I (GA1) is an autosomal recessive genetic disease caused by deficiency of glutaryl-CoA dehydrogenase (GCDH) due to pathogenic variants in the GCDH gene (19p13.2). In mitochondria, GCDH catalyzes, in a FAD-dependent manner, the oxidation of glutaryl-CoA to crotonyl-CoA in the degradation pathways of lysine, tryptophan and hydroxylysine. This reaction is an essential step in lysine and tryptophan degradation.

When GCDH is deficient, glutaryl-CoA cannot be converted to crotonyl-CoA and is instead converted to glutaric acid and 3-hydroxyglutaric acid (3-OH-GA), or glutaryl-CoA itself combines with carnitine to form glutarylcarnitine (C5DC). Glutaric acid and 3-hydroxyglutaric acid accumulate in the body, especially in the brain, and exert neurotoxicity. 3-Hydroxyglutaric acid is known to activate NMDA receptors and impair mitochondrial function, making it more strongly neurotoxic than glutaric acid.

An important pathophysiological feature is a specific vulnerability of the developing brain. The immature striatum (caudate nucleus, putamen) of the developing brain (from about 6 months to 6 years after birth) is particularly vulnerable when GCDH is deficient. If a catabolic state such as fever, infection, surgery or vaccination arises during this period, lysine degradation increases and neurotoxic metabolites rise rapidly, causing striatal damage. Because the risk of striatal damage from lysine load decreases markedly in adulthood, the 'vulnerable period' in GA1 is considered to be mainly before age 6. In addition, abnormal enlargement of the subdural space during development is observed in GA1, and excessive enlargement of this space makes subdural hemorrhage likely even with minor head trauma.


3. Genetics

The GCDH gene is located on the short arm of chromosome 19 (19p13.2) and consists of 11 exons. The mature GCDH protein has 438 amino acids, functions as a homotetramer in the mitochondrial matrix and binds FAD as a cofactor. More than 200 pathogenic variants have been reported to date, with missense variants the most common. The worldwide distribution of variants is broad, but founder variants are observed at high frequency in specific populations.

Major founder variants: p.R402W (southern Germany, parts of Europe), p.V400M (Oji-Cree First Nations of Canada, with a very high incidence of about 1 in 100), p.A293T (Amish population). A variant spectrum different from that in Western countries has been reported in Korean and Japanese GA1 patients. Some of the variants reported in Korean GA1 patients are relatively common in East Asia, but domestic molecular epidemiological data are still limited.

An important concept in the genotype–phenotype correlation in GA1 is 'excretor type': low excretors (LE) have low urinary glutaric acid excretion (< 100 mmol/mol creatinine), and blood C5DC is also within the normal range or mildly elevated, so they risk being missed on newborn tandem MS/MS screening. High excretors (HE) have high urinary glutaric acid excretion and clearly elevated C5DC and are readily detected on screening. The low excretor type accounts for about 25–30% of all GA1, and these patients are not free of the risk of neurological damage. Severe striatal crises can also occur in LE as well as HE, so excretor type does not reliably predict the risk of neurological damage.


4. General epidemiology

The overall incidence of glutaric aciduria type I is estimated at about 1 in 100,000 newborns. This varies greatly by country and population. A European study based on tandem MS/MS newborn screening data reported about 1 in 110,000, and much higher frequencies are observed in specific high-risk populations. An incidence of about 1 in 100 has been reported among the Oji-Cree First Nations in the Ontario region of Canada, one of the highest in the world. The frequency of GA1 due to the p.A293T variant is also high in the Amish population of Pennsylvania.

The sex distribution is equal (autosomal recessive), and it occurs in all ethnic groups and regions. Established data on the incidence in Korea are lacking, but since the expansion of newborn tandem MS/MS screening, cases of GA1 detected by elevated C5DC have been increasing. The number of registered patients in Korea is very small; under the rare disease registration criteria, the E72.3 code and Special Copayment Reduction V117 apply.

Before the introduction of tandem MS/MS newborn screening, GA1 was misdiagnosed as intellectual disability with dyskinesia or cerebral palsy-like symptoms, or its diagnosis was greatly delayed. Diagnosis was even more difficult particularly in the low excretor form, in which urinary glutaric acid is only slightly elevated or close to normal. Now, in countries with newborn screening, most cases are detected right after birth and treatment begins before the vulnerable period. Early treatment greatly reduces the occurrence of striatal crisis and the resulting permanent neurological damage.


5. Pathophysiology

The pathophysiology of GA1 is understood along three axes: (1) neurotoxicity of glutaric acid and 3-hydroxyglutaric acid, (2) selective developmental vulnerability of the striatum, and (3) enlargement of the subdural space.

Mechanism of neurotoxicity: Glutaric acid (GA) and 3-hydroxyglutaric acid (3-OH-GA) act as agonists or allosteric enhancers of NMDA receptors (a glutamate receptor subtype), mediating excitotoxicity. In particular, 3-OH-GA has a more potent ability to activate NMDA receptors than GA. Excessive NMDA receptor activity proceeds along the pathway of increased intracellular Ca²⁺ influx → mitochondrial dysfunction → oxidative stress → ATP depletion → cell death (excitotoxic cell death). Inhibition of GABAergic neurotransmission, inhibition of mitochondrial respiratory complex I and impaired oxidative phosphorylation also occur.

Selective developmental vulnerability of the striatum: After birth, the striatum, including the caudate nucleus and putamen, is particularly vulnerable to glutaric acid-type toxins during the period in which it matures (about 6 months to 6 years after birth). In this period, striatal neurons have high NMDA receptor expression and high energy metabolic demand, making them sensitive to toxin-induced energy depletion. Catabolic states such as fever, infection, surgery and vaccination promote lysine degradation and increase glutaryl-CoA production, and with GCDH deficient, toxic metabolites rise rapidly and trigger an acute striatal crisis. After a striatal crisis, permanent damage to the caudate nucleus and putamen occurs and dyskinesia remains.

Enlargement of the subdural space: Brain MRI of GA1 patients characteristically shows abnormal enlargement of the frontotemporal subdural space. This enlargement is due to delayed brain development or reduced brain parenchymal volume in this region. The enlarged subdural space creates a vulnerability in which bridging veins rupture easily even with minor head trauma, causing subdural hemorrhage. For this reason, when subdural hemorrhage occurs in a GA1 patient, differentiation from inflicted head trauma becomes a clinically important issue.


6. Symptoms

The clinical symptoms of GA1 are broadly divided into those before and after the occurrence of a striatal crisis. It is emphasized that if striatal crisis is prevented through early treatment and adherence to the emergency treatment protocol, normal neurodevelopment is possible in GA1 patients.

Before striatal crisis (asymptomatic phase): When diagnosed through newborn screening, patients are asymptomatic or have nonspecific symptoms until a striatal crisis. In some, macrocephaly (head circumference > 97th percentile) is the first clinical clue. Macrocephaly occurs in about 75% of GA1 patients and is associated with enlargement of the subdural space. Mild coordination disturbance during walking (ataxia) and subtle dystonia may appear even before a striatal crisis.

Acute striatal crisis: Occurs suddenly between 6 months and 5 years of age (usually most vulnerable at 12–18 months), triggered by catabolic precipitants such as febrile infections, vaccination, gastrointestinal infections, surgery and anesthesia. Rapid changes in muscle tone (hypotonia), dystonia, abnormal movements (choreoathetosis), eye deviation and developmental regression appear within hours. Seizures, decreased consciousness and fever accompany it in some, which may be mistaken for encephalitis or meningitis.

Chronic neurological symptoms after striatal crisis: Dyskinesia remains due to permanent damage to the caudate nucleus and putamen. Dystonia is the most common, and chorea and athetosis also occur. Dyskinesia seriously affects daily function and can lead to inability to walk, dysphagia and dysphonia. Intellectual function tends to be relatively preserved, but cognitive impairment also accompanies it depending on the severity of the striatal crisis.

Chronic symptoms (after the vulnerable period): In patients who have not experienced a striatal crisis or who have passed the vulnerable period (after about age 6), the risk of developing additional neurological symptoms is greatly reduced. Thereafter, white matter abnormalities and subtle neurological abnormalities may progress slowly, but they are usually much milder than a striatal crisis.


7. Signs

The diagnostic findings and physical signs of GA1 are as follows.

Brain MRI findings: These are the most characteristic imaging findings in GA1. (1) Enlargement of the frontotemporal subdural space: clearly bilateral and described as a "bat wing" or "wings" shape. (2) Striatal damage: after an acute striatal crisis, restricted diffusion of the caudate nucleus and putamen on DWI (diffusion-weighted imaging) and hyperintensity and edema on T2 appear; in the chronic phase, atrophy and residual T2 hyperintensity. (3) White matter abnormalities: abnormal periventricular white matter signal on T2. (4) In low excretors, imaging findings may be mild or absent.

Urine organic acids: Urinary glutaric acid and 3-hydroxyglutaric acid are markedly elevated (high excretors). In low excretors, they may be normal or mildly elevated. Quantification is possible by GC-MS (gas chromatography–mass spectrometry).

Plasma acylcarnitines: C5DC (glutarylcarnitine) is elevated. It is the key marker of tandem MS/MS newborn screening. C5DC may be within the normal range in low excretors.

Neurological physical signs: After an acute striatal crisis, dystonia, chorea and athetosis are observed. Abnormal deep tendon reflexes (increased or decreased), dysarthria, gait abnormalities. Macrocephaly (head circumference measurement essential).

GCDH enzyme activity: Reduced to < 10% of controls when measured in leukocytes or skin fibroblasts.


8. Screening

GA1 is included in tandem MS/MS newborn screening panels, and elevated blood C5DC (glutarylcarnitine) is the main screening marker. However, there is a limitation in that C5DC may be within the normal range in low excretors.

Newborn tandem MS/MS screening: C5DC (glutarylcarnitine) is measured on a dried blood spot (DBS). GA1 is suspected if C5DC > 0.5–1.0 μmol/L (varies by laboratory reference). Elevated C5DC is relatively specific for GA1 but does not detect all GA1. There are reports that about 20–30% of low excretor patients may be missed on screening. If screening is positive, immediate confirmatory testing (urine organic acids, plasma acylcarnitines, GCDH gene testing) is performed.

Screening in clinically suspicious situations: In infants with unexplained macrocephaly (head circumference > 97th percentile), infants with frontotemporal subdural space enlargement observed on MRI, and infants with sudden onset of dyskinesia after fever, GA1 is suspected and urine organic acid analysis and plasma acylcarnitine testing are performed. In low excretors, confirmation must be made by genetic testing even if urinary glutaric acid is normal.

Association with subdural hemorrhage: In GA1 patients, enlargement of the frontotemporal subdural space can cause subdural hemorrhage even with minor trauma. When subdural hemorrhage is found in an infant, GA1 must be included in the differential diagnosis in addition to inflicted injury.


9. Diagnosis

The diagnosis of GA1 is made by biochemical findings and molecular genetic confirmation.

Urine organic acid analysis (GC-MS): Quantification of glutaric acid and 3-hydroxyglutaric acid is key. In high excretors, both metabolites are markedly elevated; in low excretors, they may be mildly elevated or within the normal range. In particular, detection of 3-hydroxyglutaric acid even at low levels within the normal range suggests GA1.

Plasma acylcarnitine analysis: Elevated C5DC (glutarylcarnitine) is the key finding of tandem MS/MS analysis. It is interpreted together with other acylcarnitine ratios.

Brain MRI: Enlargement of the frontotemporal subdural space is characteristic of GA1, and damage to the caudate nucleus and putamen is confirmed after a striatal crisis. Rather than making a diagnosis from imaging findings alone, they are interpreted together with biochemical and genetic findings.

GCDH enzyme activity: Enzyme activity is measured in cultured skin fibroblasts or leukocytes. Less than 10% of controls is used for confirmation.

Molecular genetic confirmation: Pathogenic variants are identified by GCDH gene panel NGS. After variant identification, it is used for family counseling and prenatal diagnosis. In low excretors with mild or normal urinary glutaric acid, genetic testing is essential to confirm the diagnosis.


10. Treatment

The core goal of GA1 treatment is preventing striatal crisis. An early low-lysine diet, carnitine supplementation and strict adherence to the emergency treatment protocol (emergency regimen) in catabolic situations are most important for preventing striatal crisis.

Low-lysine diet: Because lysine is the main source of the GCDH substrate, restricting lysine intake reduces glutaric acid production. Natural protein is restricted to the minimum age-specific requirement, and amino acid formulas low in or free of lysine are supplemented to prevent essential amino acid deficiency. The target blood lysine level is maintained within the age-specific normal range. The low-lysine diet is maintained strictly especially during the vulnerable period (before age 6), after which gradual relaxation is considered.

L-carnitine supplementation: Glutaryl-CoA combines with carnitine and is converted to glutarylcarnitine (C5DC), which is excreted in the urine. Carnitine supplementation traps intracellular toxic metabolites and promotes their excretion, and prevents carnitine deficiency. L-carnitine 50–100 mg/kg/day is usually given orally.

Riboflavin (vitamin B2): There are reports that in some patients (especially with the p.R402W variant), riboflavin supplementation partially increases GCDH activity and reduces urinary glutaric acid excretion. Riboflavin responsiveness is assessed, and riboflavin is added in responsive patients.

Emergency treatment protocol for acute striatal crisis (Emergency regimen): Applied immediately when catabolic situations occur, such as fever (> 38.5°C), vomiting, anorexia or infection. ① Complete restriction of lysine intake for 24–48 hours (continued supply of lysine-free amino acid formula). ② Suppression of catabolism with a high-carbohydrate, high-glucose diet or intravenous glucose (glucose 12–15 mg/kg/min or more). ③ Increased carnitine dose. ④ Administration of antipyretics (ibuprofen or acetaminophen). ⑤ If there is no clinical improvement within 48 hours, or if decreased consciousness or dyskinesia occurs, immediate hospitalization for intravenous glucose and intensive monitoring. Rapid initiation of emergency treatment is decisive in preventing striatal damage.

Management of dyskinesia: When dyskinesia develops after a striatal crisis, baclofen, trihexyphenidyl, clonazepam, tetrabenazine and others are used on an individualized basis for symptom control. Physical therapy, occupational therapy and speech therapy are important for functional recovery and maintenance.


11. Prognosis

The prognosis of GA1 differs decisively depending on whether a striatal crisis occurs. If striatal crisis is prevented, normal neurodevelopment can be expected, but after a striatal crisis, permanent dyskinesia commonly remains.

Prognosis in patients in whom striatal crisis is successfully prevented: In patients diagnosed early through newborn screening who thoroughly adhere to a low-lysine diet, carnitine supplementation and the emergency treatment protocol, the incidence of striatal crisis decreases markedly. According to international GA1 registry data, the incidence of striatal crisis in cohorts receiving early treatment after newborn screening decreased by 70–80% compared with pre-screening cohorts. Normal intelligence and normal motor function are reported to be maintained in patients who have not experienced a striatal crisis.

Prognosis after striatal crisis: Dyskinesia (dystonia, choreoathetosis) remains due to permanent damage to the caudate nucleus and putamen. Severe dyskinesia leads to inability to walk, dysphagia and dysarthria. Some degree of function can be maintained with intensive rehabilitation and drugs to treat dyskinesia, but complete recovery from severe damage is difficult. Intellectual function tends to be relatively preserved despite striatal crisis, but there is individual variation.

Prognosis after the vulnerable period (> 6 years): Patients who pass through the vulnerable period without a striatal crisis have a greatly reduced risk of subsequent striatal damage. In adulthood, the low-lysine diet can be gradually relaxed. Mild progression of white matter abnormalities has been reported in some, but its clinical impact is small.


12. Prevention

In GA1, striatal crisis is preventable neurological damage, so thorough establishment of and adherence to prevention strategies is most important.

Early diagnosis by newborn screening: When C5DC is elevated on tandem MS/MS newborn screening, immediate confirmatory testing and initiation of treatment are key. Because low excretors may be missed on screening, GA1 should be clinically suspected and tested for when macrocephaly or frontotemporal subdural space enlargement is found on imaging.

Education on and adherence to the emergency treatment protocol: All GA1 patients and caregivers must be thoroughly educated to implement the emergency treatment protocol immediately when catabolic situations such as fever, infection, vomiting or anorexia occur. Because delay in emergency treatment causes striatal damage, immediate response at home and prompt visits to a medical institution are important. Carrying a medical alert card and sharing the contact information of the responsible metabolic specialist are necessary. During the vulnerable period (before age 6), every febrile illness is approached as a GA1 emergency.

Management around vaccination: Vaccination itself is known to be a trigger of striatal crisis in GA1 patients. If fever occurs after vaccination, the emergency treatment protocol is applied immediately. Vaccination is not avoided (rather, it is essential for preventing infection), and caregivers are educated to be prepared in advance to apply the emergency treatment protocol on the day of vaccination.

Genetic counseling and family screening: With autosomal recessive inheritance, siblings have a 25% risk of being affected. Prenatal diagnosis (CVS, amniocentesis) or preimplantation genetic testing (PGT) is considered for the next pregnancy. When the familial variant has been identified, genetic confirmatory testing of siblings is performed in the neonatal period.


13. References

  1. Kölker S, Christensen E, Leonard JV, et al. Diagnosis and management of glutaric aciduria type I—revised recommendations. J Inherit Metab Dis. 2011;34(3):677-694. DOI: 10.1007/s10545-011-9289-5. PMID: 21431622.

  2. Kölker S, Garcia-Cazorla A, Valayannopoulos V, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. J Inherit Metab Dis. 2015;38(6):1041-1057. DOI: 10.1007/s10545-015-9839-3. PMID: 25875215.

  3. Boy N, Mühlhausen C, Maier EM, et al. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision. J Inherit Metab Dis. 2017;40(1):75-101. DOI: 10.1007/s10545-016-9999-9. PMID: 27853989.

  4. Goodman SI, Markey SP, Moe PG, Miles BS, Teng CC. Glutaric aciduria: a new disorder of amino acid catabolism. Biochem Med. 1975;12(1):12-21. DOI: 10.1016/0006-2944(75)90091-5. PMID: 1167089.

  5. Zschocke J, Quak E, Guldberg P, Hoffmann GF. Mutation analysis in glutaric aciduria type I. J Med Genet. 2000;37(3):177-181. DOI: 10.1136/jmg.37.3.177. PMID: 10699054.

  6. Heringer J, Boy SP, Ensenauer R, et al. Use of guidelines improves the neurological outcome in glutaric aciduria type I. Ann Neurol. 2010;68(5):743-752. DOI: 10.1002/ana.22095. PMID: 21031484.

  7. Strauss KA, Puffenberger EG, Robinson DL, Morton DH. Type I glutaric aciduria, part 1: natural history of 77 patients. Am J Med Genet C Semin Med Genet. 2003;121C(1):38-52. DOI: 10.1002/ajmg.c.20007. PMID: 12888986.

  8. Kölker S, Cazorla AG, Valayannopoulos V, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. J Inherit Metab Dis. 2015;38(6):1059-1074. DOI: 10.1007/s10545-015-9840-x. PMID: 25875216.

  9. Boy N, Garbade SF, Heringer J, Seitz A, Kölker S, Harting I. Extrastriatal changes in the spectrum of acute MRI features in glutaric aciduria type 1. J Inherit Metab Dis. 2019;42(1):82-93. DOI: 10.1007/s10545-018-0226-6. PMID: 30374916.

  10. Lee HJ, Yoo HW, Cho HJ, et al. Glutaric aciduria type 1 in Korean patients: clinical, biochemical and genetic features. J Inherit Metab Dis. 2013;36(2):319-325. DOI: 10.1007/s10545-012-9526-4. PMID: 22825603.